Trametinib + Azacitidine for Myelomonocytic Leukemia
Trial Summary
What is the purpose of this trial?
This clinical trial will test the safety and efficacy of combining trametinib and azacitidine in patients with juvenile myelomonocytic leukemia (JMML). Newly diagnosed lower-risk JMML patients will receive trametinib and azacitidine. High-risk JMML patients will receive trametinib, azacitidine, fludarabine, and cytarabine.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but you cannot have had prior leukemia-directed therapy, except for certain medications like hydroxyurea and 6-mercaptopurine shortly before starting the trial. It's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug combination Trametinib + Azacitidine for Myelomonocytic Leukemia?
Azacitidine has been shown to improve survival in patients with chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS), and it is considered a standard treatment for higher-risk MDS. Combining Azacitidine with other drugs has been suggested to potentially enhance outcomes, although specific data on Trametinib in this combination is not provided.12345
Is the combination of Trametinib and Azacitidine safe for treating myelomonocytic leukemia?
Azacitidine has been studied extensively and is generally considered safe for treating conditions like myelomonocytic leukemia, though it can cause side effects such as anemia (low red blood cell count), neutropenia (low white blood cell count), and fatigue. Most side effects can be managed with additional medications, and treatment discontinuation due to side effects is rare.678910
What makes the drug combination of Trametinib and Azacitidine unique for treating myelomonocytic leukemia?
The combination of Trametinib and Azacitidine is unique because it combines a MEK inhibitor (Trametinib) with a hypomethylating agent (Azacitidine), potentially offering a novel mechanism of action compared to traditional treatments. This combination may provide enhanced efficacy by targeting different pathways involved in leukemia cell growth and survival.28111213
Eligibility Criteria
This trial is for children and young adults up to 21 years old with newly diagnosed juvenile myelomonocytic leukemia (JMML). Participants must meet specific diagnostic criteria, including spleen enlargement, high monocyte counts, and no BCR/ABL fusion gene. They should also have a RAS mutation or clinical diagnosis of neurofibromatosis type 1.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Lower-risk patients receive daily azacitidine for 5 days and trametinib for 28 days per course for up to 12 courses. High-risk patients receive daily azacitidine, fludarabine, and cytarabine for 5 days and trametinib for 28 days per course for up to 2 courses.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including the incidence of dose limiting toxicities (DLTs) after the 1st course of therapy.
Treatment Details
Interventions
- Azacitidine (Nucleoside Analog)
- Cytarabine (Nucleoside Analog)
- Fludarabine (Nucleoside Analog)
- Trametinib (MEK Inhibitor)
Azacitidine is already approved in European Union, United States, Canada, Japan, Australia for the following indications:
- Acute myeloid leukemia
- Chronic myelomonocytic leukemia
- Myelodysplastic syndromes
- Myelodysplastic syndromes
- Chronic myelomonocytic leukemia
- Myelodysplastic syndromes
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Acute myeloid leukemia